Login to Your Account

Clinic Roundup

Wednesday, September 26, 2012
• Seattle Genetics Inc., of Bothell, Wash., and Millennium: The Takeda Oncology Co., of Cambridge, Mass., completed patient enrollment in a Phase III trial of Adcetris (brentuximab vedotin) in post-transplant Hodgkin lymphoma (HL).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription